Takeda unveils data on dengue vaccine
Takeda unveiled promising data for its experimental dengue vaccine over the weekend, but those results come with an asterisk.
The company presented 18-month data from a Phase 3 trial outlining the vaccine’s efficacy against the debilitating virus — and showed it was 73% effective at preventing the disease in vaccinated children. It also reduced the risk of hospitalization by 90%. Those numbers are strong, particularly when noting that Sanofi's Dengvaxia vaccine cannot be given to children who’ve never been infected with dengue. (It appears to increase their risk of developing serious illness if they subsequently contract the virus.)
The company presented 18-month data from a Phase 3 trial outlining the vaccine’s efficacy against the debilitating virus — and showed it was 73% effective at preventing the disease in vaccinated children. It also reduced the risk of hospitalization by 90%. Those numbers are strong, particularly when noting that Sanofi's Dengvaxia vaccine cannot be given to children who’ve never been infected with dengue. (It appears to increase their risk of developing serious illness if they subsequently contract the virus.)
Still, the Takeda product had some serious holes in its efficacy against the dengue 3 strain of the disease — particularly among children who had never been infected with dengue before.
.png)
No hay comentarios:
Publicar un comentario